Comparing a new diabetes combination to standard care for type 2 diabetes
Part of Hormones & metabolism clinical trials.
This trial tests if a once-daily injectable combination (iGlarLixi) helps control blood sugar better than usual care for people with type 2 diabetes who are already taking diabetes pills. It aims to find a more effective treatment option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with type 2 diabetes.
- You have been taking 1 to 3 diabetes pills for at least 3 months.
- Your HbA1c (average blood sugar over 3 months) is between 7.5% and 11%.
- Your doctor thinks you need to start an injectable diabetes medicine.
- You are not pregnant, breastfeeding, or plan to become pregnant during the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three diabetes medicines (henagliflozin proline, retagliptin, and metformin) for people newly diagnosed with type 2 diabetes. The goal is to see how well the combination controls blood sugar and to check its safety.
This study tests a new once-daily insulin (GZR4) against an approved insulin (degludec) in people with type 2 diabetes to see how well it controls blood sugar. You may qualify if you are already using a stable dose of background insulin.
This study looks at what happens when people with type 2 diabetes switch from a short course of intensive insulin therapy to different daily diabetes medicines. It aims to find which option helps keep blood sugar under control and might be easier for you.
This study tests a new once-weekly injectable medication (HDM1005) for people with type 2 diabetes whose blood sugar is not well controlled by diet and exercise or metformin alone. It aims to help lower blood sugar and may also support weight loss.
This study tests a new daily pill (QLG1091) against a similar existing pill (Rybelsus) when both are added to your current metformin treatment for type 2 diabetes. The goal is to see if the new pill is as effective and safe for lowering blood sugar.
This study tests a combination insulin/GLP-1 medicine (iGlarLixi) with continuous glucose monitoring to see how well it controls blood sugar in Chinese adults with type 2 diabetes. It may help those whose current pills are not working enough.
Hear when a new Type 2 diabetes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.